Vigil Neuroscience, Inc. Board of Directors

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Dr. David Gray Ph.D.

Dr. David Gray Ph.D.

Chief Scientific Officer

Christian Mirescu Ph.D.

Christian Mirescu Ph.D.

Senior VP & Head of Neuroimmunology

Weeteck Yeo Ph.D.

Weeteck Yeo Ph.D.

Senior Vice President of Strategic Operations

Mr. Evan A. Thackaberry DABT, Ph.D.

Mr. Evan A. Thackaberry DABT, Ph.D.

Senior VP & Head of Early Development

Eric Brophy

Eric Brophy

Senior Manager of Information Technology

Ms. Leah Gibson

Ms. Leah Gibson

Vice President of Investor Relations and Corporate Communications

Sharon Morani

Sharon Morani

Senior Director of Facilities & Operations

April Effort M.B.A., M.S.

April Effort M.B.A., M.S.

VP & Head of Corporate Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.